Navigation Links
GenVec Announces Update of Safety and Efficacy Data from Pivotal,Phase II/III PACT Study of TNFerade at ASCO

Ferade(TM), is currently in a pivotal Phase II/III study (PACT) in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and seasonal and pandemic flu. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Preliminary clinical trial data cannot be considered predictive of final trial outcome. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Excha
'"/>




Page: 1 2 3 4

Related medicine technology :

1. GenVec Presents Research on New Ad35 Adenovector at ARVO
2. GenVec Announces New Research at AACR on Selectivity and Mechanism of Action of TNF-Based Anti-Cancer Therapy
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:1/23/2015)... 2015  The Partnership to Fight Chronic Disease (PFCD) released a public ... and a new study analyzing the impact of increased cost sharing ... coalition working to educate policy makers and the public on the ... focused on how the Iowa healthcare exchange ...
(Date:1/23/2015)... BETHESDA, Md. , Jan. 23, 2015  Northwest Biotherapeutics, Inc. ... developing DCVax® personalized immune therapies for operable and inoperable solid ... will present at the 7 th Annual Phacilitate Immunotherapy ... NW Bio,s presentation at Phacilitate will take place on January ...
(Date:1/23/2015)... than a third of reproductive-aged women enrolled in Medicaid, and ... a prescription for an opioid pain medication each year during ... Mortality Weekly Report (MMWR). Opioids are typically ... pain.  They are also found in some prescription cough medications. ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... 25, 2011 PDI, Inc. (Nasdaq: ... and commercialization services to health care companies, today announced ... 10 pharmaceutical company has been renewed for an additional ... Shared Sales team beginning in September 2011 through March ...
... 2011 Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN ) ... who has conducted multiple clinical studies of zinc lozenges for the ... Mr. Eby is a pioneer in the development of zinc ... more than 30 years to the study of zinc and is ...
Cached Medicine Technology:PDI Announces Renewal of Engagement for 7th Consecutive Season 2Adeona Appoints George A. Eby to Scientific Advisory Board 2Adeona Appoints George A. Eby to Scientific Advisory Board 3Adeona Appoints George A. Eby to Scientific Advisory Board 4
(Date:1/22/2015)... 2015 The Incredible Bulk is a revolutionary ... increase lean muscle by up to 30lbs in less than ... of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... step-by-step, scientific diet formula that allows the body to pack ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David ... Show to bestow a Juvent Sports Achievement award upon ... McKitrick. The award commemorated and congratulated McKitrick for her ... won her first amateur tournament in 1979 and most ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Carinsurancesavings.biz has released ... accidental death and dismemberment insurance . , Purchasing an ... can be very advantageous. This type of rider provides benefits ... dismemberment can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative ... design to treat specific body parts and muscle groups. , ... easy to use patented cold therapy machine with the innovative ... and muscle injuries. IsoComforter has become the industry leader ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 JJsHouse.com is a ... dresses. Today, the business announces its latest collection of ... , “The most important issue is the wedding dress on ... thing in a woman’s life. Every bride wants to find ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... to Present September,22-24, 2008, WASHINGTON, Sept. ... medical technology companies have been selected to ... presentations offer a unique,business development and information ... the cardiovascular, dental, diagnostics, imaging,metabolic disease/obesity, neurology, ...
... - U.S. Preventive Medicine, Inc.,( http://www.USPreventiveMedicine.com ), the ... Ron Loeppke, M.D., MPH, as Co-Chairman of,the company,s ... researching,the role of primary, secondary and tertiary prevention ... health and,productivity in the workplace, as well as ...
... 1 in U.S. ... ... Inc. and Orphan Therapeutics, LLC announced today that they have,entered into an ... from Orphan Therapeutics., Orphan Therapeutics has initiated a rolling NDA with ...
... 2 The Diversified Agency Services (DAS),unit ... to the position of,Executive Vice President and ... position Sharon will direct the client-centric and,brand-centric ... a,worldwide multidisciplinary resource of specialist agencies that ...
... Sept. 2 September is Cholesterol,Awareness Month. The ... perceived failures in drug trials, Tim Russert,s sudden,death, ... of dyslipidemia in,children have all led to increased ... views these developments as reinforcing the importance of ...
... finding is ,good news, for postmenopausal women taking ... Contrary to previous study results, the cancer prevention ... of cognitive performance, a new study found. ... to tamoxifen in preventing breast cancer recurrence in ...
Cached Medicine News:Health News:Canadian, German, Israeli, New Zealand, U.K and U.S. Companies Selected to Make Company Presentations at AdvaMed 2008 2Health News:Canadian, German, Israeli, New Zealand, U.K and U.S. Companies Selected to Make Company Presentations at AdvaMed 2008 3Health News:Canadian, German, Israeli, New Zealand, U.K and U.S. Companies Selected to Make Company Presentations at AdvaMed 2008 4Health News:U.S. Preventive Medicine Appoints Ron Loeppke, M.D. as Co-Chairman of Its National Advisory Board 2Health News:U.S. Preventive Medicine Appoints Ron Loeppke, M.D. as Co-Chairman of Its National Advisory Board 3Health News:Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics 2Health News:Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics 3Health News:Sharon Callahan Joins Diversified Agency Services Unit of Omnicom Group 2Health News:Cholesterol Awareness Month: Americans Urged to Seek Early Intervention 2Health News:Breast Cancer Drug Not Tied to Cognitive Decline: Study 2
... Artis FC is a floor-mounted, ... flexible system architecture for vascular ... The flexible and ergonomic system ... adapt the system configuration to ...
The ACUSON Sequoia C512 system elevates imaging and Doppler performance through new, high-density acoustic sampling, precise control of the transmitted acoustic waveform, and new transducer technolog...
... cardioangiography procedures with MR imaging results and ... Utilize your angio and MR system at ... suite. Because the systems can be combined ... follow-up in one room, one control room ...
... every beating heart at any heart rate and ... scanner using two X-ray sources and two detectors ... in acute care; even with large patients, regardless ... Cardiac Engine, a unique combination of Siemens innovative ...
Medicine Products: